Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleClinical Studies

How the Measurements of a Few Serum Markers Can Be Combined to Enhance their Clinical Values in the Management of Cancer

OSCAR J. CORDERO, LORETTA DE CHIARA, YOHANNA LEMOS-GONZÁLEZ, MARÍA PÁEZ DE LA CADENA and FRANCISCO J. RODRÍGUEZ-BERROCAL
Anticancer Research July 2008, 28 (4C) 2333-2341;
OSCAR J. CORDERO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bnojcord@usc.es
LORETTA DE CHIARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHANNA LEMOS-GONZÁLEZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARÍA PÁEZ DE LA CADENA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCISCO J. RODRÍGUEZ-BERROCAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The number of potential molecular markers is constantly increasing. However, for most malignancies there is no simple test to detect early-stage tumours that is useful for screening purposes because most biomarkers have poor sensitivity or specificity, or other clinical value. One approach to increase their value is to measure several biomarkers at a time. The additional information should always yield a test more able to distinguish between patients and healthy individuals, and ideally between different kinds of tumour. Our work in colorectal, lung, and head and neck cancer, illustrates the evolution of this idea. A test in which ELISAs for key serum markers are arrayed based on immunoblot technology or flow cytometric beads is suggested because these techniques are more transferable to practical application in clinical decision making. Moreover, the multivariate data obtained from such a test can easily be managed with statistical methods already developed in the fields of genomics and proteomics.

  • Cancer
  • lung
  • colorectal
  • head and neck
  • biomarkers
  • serum
  • screening
  • diagnosis
  • prognosis
  • sCD26
  • EGF
  • sEGFR
  • ELISA
  • cytometric beads
  • antibody arrays
  • clustering
  • bioinformatics
  • review

Footnotes

  • Received January 29, 2008.
  • Revision received May 19, 2008.
  • Accepted May 22, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How the Measurements of a Few Serum Markers Can Be Combined to Enhance their Clinical Values in the Management of Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
How the Measurements of a Few Serum Markers Can Be Combined to Enhance their Clinical Values in the Management of Cancer
OSCAR J. CORDERO, LORETTA DE CHIARA, YOHANNA LEMOS-GONZÁLEZ, MARÍA PÁEZ DE LA CADENA, FRANCISCO J. RODRÍGUEZ-BERROCAL
Anticancer Research Jul 2008, 28 (4C) 2333-2341;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
How the Measurements of a Few Serum Markers Can Be Combined to Enhance their Clinical Values in the Management of Cancer
OSCAR J. CORDERO, LORETTA DE CHIARA, YOHANNA LEMOS-GONZÁLEZ, MARÍA PÁEZ DE LA CADENA, FRANCISCO J. RODRÍGUEZ-BERROCAL
Anticancer Research Jul 2008, 28 (4C) 2333-2341;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Exhaled biomarkers in lung cancer
  • Google Scholar

More in this TOC Section

  • Impact of Nivolumab Plus Chemotherapy on Conversion Therapy in Clinical Stage IVB HER2-negative Gastric Cancer
  • Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
  • Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire